HC Wainwright & Co. Maintains Buy on Intellia Therapeutics, Lowers Price Target to $25

Benzinga Newsdesk www.benzinga.com Neutral 59.4%

Neg 0% Neu 59.4% Pos 0%

HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Intellia Therapeutics (NASDAQ:NTLA) with a Buy and lowers the price target from $30 to $25.